Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
we propose to randomize patients with hormone resistant prostate cancer between
docetaxel/estramustine/prednisone and docetaxel/prednisone in a phase II study. The principal
endpoint will be the efficacy in term of PSA response.
Phase:
Phase 2
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain